Clinical and Experimental Dermatology最新文献

{"title":"Psychocutaneous medicine: current global understanding and imperatives for continuing medical education and training opportunities. A systematic review.","authors":"Isabella J Tan, Olivia M Katamanin, Jillian Barry, Mohammad Jafferany","doi":"10.1093/ced/llae484","DOIUrl":"10.1093/ced/llae484","url":null,"abstract":"<p><p>The intersection of dermatology and psychiatry has gained significant attention in recent years. Psychocutaneous disease affects patient populations who have undiagnosed and undertreated ailments related to the body and mind. These patients have a reduced quality of life due to knowledge gaps and reduced awareness about psychodermatology. This review aims to assess the integration of psychopharmacology topics into continuing medical education (CME) programmes. The review will cover the relevance of CME in clinical practice, its impact on healthcare professionals' quality of care, and existing knowledge gaps among trainees and young dermatologists. To identify data from inception up to December 2023, a systematic literature review and search was conducted following the PRISMA guidelines. The study was registered with PROSPERO (CRD42023494609). The PubMed, Cochrane and Embase databases were searched using predefined terms including 'continuing medical education', 'dermatology', 'psychology', 'psychodermatology', 'psychocutaneous', 'awareness' and 'practice patterns'. Inclusion criteria comprised studies evaluating CME programmes, clinical studies and reviews; and publications in the English language. Studies were excluded if they were single case reports. In total, 93 studies were identified, and 12 were included in this review following screening, removal of duplicates and application of the inclusion criteria. The studies revealed lower levels of confidence among professionals in handling psychocutaneous conditions, limited awareness of available resources and high interest in CME programmes. Initiatives like video mentoring and clinical skills lessons showed promise but are currently scarce. Examined data from selected studies demonstrate that current CME programmes in psychodermatology lack depth, leaving practitioners feeling ill equipped and unaware of available resources. There is substantial global interest in enhancing these programmes. Given the breadth of conditions covered, educating dermatologists is crucial for enhanced patient outcomes and satisfaction. Addressing resource scarcity and patient stigma is imperative to developing specialized programmes. Improvement to education can drive stronger outcomes and holistic patient care. Future efforts should prioritize refining programme strategies and conducting thorough assessments to maximize impact.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"740-746"},"PeriodicalIF":3.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitor-induced bullous pemphigoid: Evidence of dose dependency from two case studies.","authors":"Evdoxia Panou, Ioannis-Alexios Koumprentziotis, Christos Nikolaou, Antonios Tsimpidakis, Alexander Stratigos, Vasiliki Nikolaou","doi":"10.1093/ced/llaf140","DOIUrl":"https://doi.org/10.1093/ced/llaf140","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toxocariasis as a trigger for inflammatory skin disorders: a practical case series from French Guiana.","authors":"Juliette Lebret, Aude Valois, Geoffrey Grotta, Celine Michaud, Magalie Demar, Romain Blaizot","doi":"10.1093/ced/llae412","DOIUrl":"10.1093/ced/llae412","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"861-863"},"PeriodicalIF":3.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three-dimensional stereophotogrammetry: an effective tool for detecting disease progression in lupus erythematosus panniculitis.","authors":"Kimberly B Hashemi, Laura I Ortiz-López, Karla M Santiago-Soltero, Tyler T Nguyen, Rochelle L Castillo, Fatma Dedeoglu, Ingrid M Ganske, Katharina S Shaw, Ruth Ann Vleugels","doi":"10.1093/ced/llae504","DOIUrl":"10.1093/ced/llae504","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"901-903"},"PeriodicalIF":3.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142680951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refractory benign familial pemphigus successfully treated with dupilumab: a case series.","authors":"Ana Simon Gozalbo, Cristina Mauleon Fernandez, Raquel Carrascosa de Lome, Maria A Martin Diaz, Pablo de la Cueva Dobao","doi":"10.1093/ced/llae507","DOIUrl":"10.1093/ced/llae507","url":null,"abstract":"<p><p>Benign familial pemphigus (BFP) is a chronic autosomal dominant genodermatosis characterized by the appearance of flaccid blisters that progress to painful erythematous macerated plaques and erosions in intertriginous areas. Although various treatments for BFP exist, current treatments are not consistently effective, and BFP symptoms often cause a decreased quality of life. We report a case series of three patients with refractory moderate-to-severe BFP who were successfully treated with dupilumab. We also describe their clinical evolution over a follow-up period of 18 months. All patients reported a decrease in pruritus and improved skin findings, with no adverse side-effects. However, increased dosing was required in one patient to achieve optimal control of the disease. We also discuss previously reported cases of BFP treated with biologics. Dupilumab appears to be a useful and safe treatment option for patients with refractory BFP.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"841-844"},"PeriodicalIF":3.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laser Treatment of Male Genital Dermatoses.","authors":"Vishal Madan","doi":"10.1093/ced/llaf135","DOIUrl":"https://doi.org/10.1093/ced/llaf135","url":null,"abstract":"<p><p>Laser therapy has emerged as a valuable treatment modality for various male genital dermatoses, offering precise targeting of pathological tissue while minimising damage to surrounding healthy structures. Different laser systems, including CO2, Nd: YAG, and PDL lasers, have effectively treated conditions such as condylomata acuminata, lichen sclerosus, angiokeratomas, and other male genital conditions. This review evaluates the current evidence for laser interventions across different male genital dermatoses, examining treatment protocols, efficacy data, and safety considerations. While CO2 laser has successfully been used to treat genital warts and hyperkeratotic lesions, vascular-specific lasers like PDL and Nd: YAG have proven effective for vascular and pigmented disorders. However, the evidence base predominantly comprises case reports, small case series, and retrospective studies, with limited high-quality randomised controlled trials. Treatment outcomes are generally promising and tolerable, but standardised protocols and robust comparative studies are needed to establish optimal treatment parameters and long-term efficacy.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurofibromatosis type 1 presenting as congenital glaucoma with associated plexiform neurofibroma.","authors":"Cathal O'Connor, Danielle Vincent, Mary Bennett, Niamh McSweeney","doi":"10.1093/ced/llaf136","DOIUrl":"https://doi.org/10.1093/ced/llaf136","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple painful acral nodules with ulceration.","authors":"Arun Somasundaram, Swaathi Ramesh, Avanija Sai Gajula, Sivaranjini Ramassamy, Kanwalpreet Kaur","doi":"10.1093/ced/llaf138","DOIUrl":"https://doi.org/10.1093/ced/llaf138","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-Term Biologic Therapy for Guttate Psoriasis: Successful Treatment with Bimekizumab and Literature Review.","authors":"Daniella Kushnir-Grinbaum, Michael Ziv, Rodney D Sinclair","doi":"10.1093/ced/llaf137","DOIUrl":"https://doi.org/10.1093/ced/llaf137","url":null,"abstract":"<p><p>Guttate psoriasis is a psoriasis subtype often triggered by infections that may progress to chronic plaque psoriasis. While some cases resolve on their own, severe cases can be challenging to manage. Our case, along with recent reports, suggests that interim treatment with biologics such as IL-17 and IL-23 inhibitors may induce long-term remission. Further research is needed to explore the potential role of biologics as a therapeutic option for this condition.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variability in Triple Bottom Line commitments of Multinational Pharmaceutical and Cosmeceutical Companies: Insights from 2023 Corporate and ESG Reports.","authors":"Rebecca Grant, Dennis Niebel, William Hunt, Simon Tso","doi":"10.1093/ced/llaf133","DOIUrl":"https://doi.org/10.1093/ced/llaf133","url":null,"abstract":"<p><p>The triple bottom line is a framework for evaluating organisational performance incorporating environmental, social and economic impacts. This study examined the triple bottom line commitments of multinational corporates operating in the dermatology field with a specific focus on environmental goals. A convenience sample of 10 pharmaceuticals and 6 cosmeceuticals corporates were included in this study. We performed a retrospective secondary data analysis of their published 2023 corporate annual reports and environmental, social and governance (ESG) reports, and reviewed their commitments. Results showed all corporates except 3 pharmaceuticals (81%; 13/16) published a target year to reach carbon net zero or neutrality for GHG scopes 1 and 2 (median year = 2040; range = 2025-2050; 95% confidence interval (CI) = 2035-2045). All corporates except 4 pharmaceuticals (75%; 12/16) published a target year to reach carbon net zero or neutrality for GHG scope 3 (median year = 2043; range 2026-2050; 95% CI = 2038-2047). All net zero or carbon neutrality plans identified have outlined the potential inclusion or actual utilisation of carbon offsetting schemes or carbon removal schemes in achieving their goals. All corporates except one (84.4%; 5/6) cosmeceuticals are part of the EcoBeauty Consortium. This study highlighted variability in their ambitions in environmental goals.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}